BCL2 and acute myeloid leukemia: Furthermore, using PDX models, the PRC2-NSD2/3-mediated MYC regulatory pathway has been identified as a drug-induced antagonistic pleiotropy pathway that confers resistance to bromodomain and BCL-2 inhibitors in AML (221).